Johnson & Johnson JNJ
We take great care to ensure that the data presented and summarized in this overview for JOHNSON & JOHNSON is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JNJ
View all-
Vanguard Group Inc Valley Forge, PA231MShares$33.6 Billion0.69% of portfolio
-
Black Rock Inc. New York, NY198MShares$28.8 Billion0.67% of portfolio
-
State Street Corp Boston, MA134MShares$19.5 Billion0.9% of portfolio
-
Geode Capital Management, LLC Boston, MA56.1MShares$8.15 Billion0.75% of portfolio
-
Morgan Stanley New York, NY45.2MShares$6.56 Billion0.54% of portfolio
-
Jpmorgan Chase & CO New York, NY33.8MShares$4.91 Billion0.45% of portfolio
-
State Farm Mutual Automobile Insurance CO Bloomington, IL31.7MShares$4.6 Billion4.47% of portfolio
-
Northern Trust Corp Chicago, IL27.4MShares$3.99 Billion0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD25.2MShares$3.66 Billion0.47% of portfolio
-
Bank Of America Corp Charlotte, NC24.7MShares$3.58 Billion0.34% of portfolio
Latest Institutional Activity in JNJ
Top Purchases
Top Sells
About JNJ
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Insider Transactions at JNJ
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 12
2024
|
Mark A Weinberger Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$147,000
$147.22 P/Share
|
Oct 17
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Bona fide gift
|
Indirect |
68,835
+50.0%
|
-
|
Oct 17
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Bona fide gift
|
Direct |
68,835
-100.0%
|
-
|
Aug 30
2024
|
Robert J Decker VP Corporate Controller |
SELL
Open market or private sale
|
Direct |
5,635
-22.9%
|
$929,775
$165.06 P/Share
|
Aug 30
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
5,635
+18.63%
|
$563,500
$100.06 P/Share
|
Jul 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
5,018
-20.19%
|
$737,646
$147.16 P/Share
|
Jul 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
9,809
+28.3%
|
-
|
May 22
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Bona fide gift
|
Direct |
55
-0.08%
|
-
|
May 01
2024
|
John C Reed EVP, Innovative Medicine, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
10,984
-48.69%
|
$1,581,696
$144.59 P/Share
|
May 01
2024
|
John C Reed EVP, Innovative Medicine, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
22,255
+49.66%
|
-
|
Mar 13
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Open market or private sale
|
Direct |
8,891
-37.15%
|
$1,440,342
$162.16 P/Share
|
Feb 13
2024
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-0.45%
|
$13,502
$157.85 P/Share
|
Feb 13
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
313
+1.62%
|
-
|
Feb 13
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
209
-0.87%
|
$32,813
$157.85 P/Share
|
Feb 13
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
408
+1.66%
|
-
|
Feb 13
2024
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-2.75%
|
$37,052
$157.85 P/Share
|
Feb 13
2024
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+7.06%
|
-
|
Feb 13
2024
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
1,507
-0.41%
|
$236,599
$157.85 P/Share
|
Feb 13
2024
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
3,470
+0.94%
|
-
|
Feb 13
2024
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
427
-1.09%
|
$67,039
$157.85 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 449K shares |
---|---|
Open market or private purchase | 1K shares |
Bona fide gift | 68.8K shares |
Grant, award, or other acquisition | 790 shares |
Payment of exercise price or tax liability | 225K shares |
---|---|
Open market or private sale | 73.9K shares |
Bona fide gift | 68.9K shares |